european_commission_web

EMA review confirms risks of Abbvie and Biogen’s Zinbryta outweigh benefits

pharmafile | May 21, 2018 | News story | Research and Development, Sales and Marketing EMA, Europe, European Commission, PRAC, multiple sclerosis, pharma, zinbryta 

The EMA has judged that the benefits offered by Zinbryta (daclizumab), Abbvie and Biogen’s humanised IgG1 monoclonal antibody for the treatment of multiple sclerosis (MS), do not outweigh its risks, following a review carried out by the agency’s Pharmacovigilance Risk Assessment Committee (PRAC) at the request of the European Commission.

The PRAC confirmed that the drug “poses a risk of serious and potentially fatal immune reactions affecting the brain, liver and other organs”, and that “patients could be at risk from the start of treatment and for several months after stopping treatment, and it is not possible to predict which patients will be affected”.

The investigation followed 12 reports linking Zinbryta to cases of inflammatory brain disorders around the world such as encephalitis and meningoencephalitis, with three cases resulting in death. On 6 March, the PRAC recommended that the product be pulled from the European market, and by 27 March, Biogen and Abbvie voluntarily withdrew the drug from all markets.

Advertisement

Despite the fact that the review confirmed the PRAC’s original recommendation, there will be no immediate impact of the findings as Zinbryta is not currently authorised in the EU. The drug was first awarded approval in the region in 2016 for the treatment of relapsing forms of MS in adults.

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

EMA selects TrialAssure anonymisation platform for clinical trial documents

TrialAssure has announced that its ANONYMIZE platform has been selected by the European Medicines Agency …

The Gateway to Local Adoption Series

Latest content